A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

Recruiting

Phase 2

KT-621A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

Sponsor:

Kymera Therapeutics, Inc.

Code:

NCT07217015

Conditions

Atopic Dermatitis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

KT-621

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-22. This information was provided to ClinicalTrials.gov by Kymera Therapeutics, Inc. on 2025-10-15.